Summary：**Metis TechBio AI Life Science Firm Excitedly Awaits Hong Kong IPO Debut** *Introduction* Metis T

**Metis TechBio AI Life Science Firm Excitedly Awaits Hong Kong IPO Debut**

*Introduction*
Metis TechBio, a Hong Kong‑based pioneer that fuses artificial intelligence with life‑science research, is counting down to its initial public offering on the Hong Kong Stock Exchange. The firm, which has spent the last five years building a platform that predicts protein‑drug interactions with unprecedented speed, says the listing will provide the capital needed to expand its pipeline and accelerate global partnerships.

*Key Developments*
In the past twelve months, Metis TechBio announced three major milestones: the completion of a Series C round that raised US$120 million from sovereign wealth funds and venture capitalists; the signing of a joint‑development agreement with a leading European pharmaceutical company to co‑create oncology candidates; and the launch of a cloud‑based AI toolkit that allows academic labs to run virtual screens without heavy computational infrastructure. These achievements have pushed the company’s valuation past the HK$8 billion mark, according to sources close to the deal.

*Industry Analysis*
The intersection of AI and biotechnology is no longer a niche experiment; it is becoming a core driver of drug‑discovery efficiency. Analysts estimate that AI‑enabled platforms can cut early‑stage research timelines by up to 40 % and reduce failure rates in preclinical trials. Metis TechBio’s proprietary deep‑learning models, trained on over 200 million molecular structures, give it a competitive edge in identifying hit compounds that traditional high‑throughput screening might miss. Moreover,